Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
Posted on Wed, May 04, 2011
Neurology, 05/04/2011 Clinical Article
French JA et al. – This study demonstrates that EZG(RTG) is effective as add-on therapy for reducing seizure frequency in patients with drug-resistant partial-onset seizures.
Methods
- RESTORE 1 was a multicenter, randomized, double-blind, parallel-group trial.
- Following a prospective 8-week baseline phase, patients entered an 18-week double-blind treatment period (6-week forced dose titration to EZG[RTG] 1,200 mg/day in 3 equally divided doses or placebo, followed by a 12-week maintenance phase).
- Results were analyzed on an intent-to-treat basis for the entire 18-week period and for patients reaching the maintenance phase.